Literature DB >> 24180360

Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties.

Kathleen M Morrow1, Joseph L Fava, Rochelle K Rosen, Sara Vargas, Julia G Shaw, E Milu Kojic, Patrick F Kiser, David R Friend, David F Katz.   

Abstract

Abstract The effectiveness of any biomedical prevention technology relies on both biological efficacy and behavioral adherence. Microbicide trials have been hampered by low adherence, limiting the ability to draw meaningful conclusions about product effectiveness. Central to this problem may be an inadequate conceptualization of how product properties themselves impact user experience and adherence. Our goal is to expand the current microbicide development framework to include product "perceptibility," the objective measurement of user sensory perceptions (i.e., sensations) and experiences of formulation performance during use. For vaginal gels, a set of biophysical properties, including rheological properties and measures of spreading and retention, may critically impact user experiences. Project LINK sought to characterize the user experience in this regard, and to validate measures of user sensory perceptions and experiences (USPEs) using four prototype topical vaginal gel formulations designed for pericoital use. Perceptibility scales captured a range of USPEs during the product application process (five scales), ambulation after product insertion (six scales), and during sexual activity (eight scales). Comparative statistical analyses provided empirical support for hypothesized relationships between gel properties, spreading performance, and the user experience. Project LINK provides preliminary evidence for the utility of evaluating USPEs, introducing a paradigm shift in the field of microbicide formulation design. We propose that these user sensory perceptions and experiences initiate cognitive processes in users resulting in product choice and willingness-to-use. By understanding the impact of USPEs on that process, formulation development can optimize both drug delivery and adherence.

Mesh:

Substances:

Year:  2013        PMID: 24180360      PMCID: PMC3931431          DOI: 10.1089/AID.2013.0099

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  51 in total

1.  Predicting subjective spreadability, viscosity, and stickiness.

Authors:  M L DeMartine; E L Cussler
Journal:  J Pharm Sci       Date:  1975-06       Impact factor: 3.534

Review 2.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

3.  Assessing microbicide acceptability: a comprehensive and integrated approach.

Authors:  Kathleen M Morrow; Monica S Ruiz
Journal:  AIDS Behav       Date:  2007-06-26

4.  A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.

Authors:  Anatoli Kamali; Helen Byomire; Catherine Muwonge; Julie Bakobaki; Clare Rutterford; Pius Okong; Albert Profy; Romano Byaruhanga; Stella Namukwaya; Sheena McCormack; Heiner Grosskurth; Andrew J Nunn; Charles J N Lacey
Journal:  Sex Transm Infect       Date:  2010-05-05       Impact factor: 3.519

5.  Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.

Authors:  Anthony S Ham; Shweta R Ugaonkar; Lianjun Shi; Karen Watson Buckheit; Howard Lakougna; Umadevi Nagaraja; Garry Gwozdz; Laurie Goldman; Patrick F Kiser; Robert W Buckheit
Journal:  J Pharm Sci       Date:  2012-01-06       Impact factor: 3.534

6.  Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.

Authors:  Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

7.  Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide.

Authors:  Savas Tasoglu; David F Katz; Andrew J Szeri
Journal:  J Nonnewton Fluid Mech       Date:  2012-11       Impact factor: 2.670

8.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

Review 9.  Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Gustavo F Doncel
Journal:  Infect Dis Obstet Gynecol       Date:  2011-08-09

10.  Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa.

Authors:  Gita Ramjee; Neetha S Morar; Sarah Braunstein; Barbara Friedland; Heidi Jones; Janneke van de Wijgert
Journal:  AIDS Res Ther       Date:  2007-09-27       Impact factor: 2.250

View more
  23 in total

1.  Achieving the optimal vaginal state: using vaginal products and study gels in Uganda, Zimbabwe, and South Africa.

Authors:  Zoe Duby; Barbara Mensch; Miriam Hartmann; Elizabeth Montgomery; Imelda Mahaka; Linda-Gail Bekker; Ariane van der Straten
Journal:  Int J Sex Health       Date:  2017-03-27

2.  Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.

Authors:  Rochelle K Rosen; Jacob J van den Berg; Sara E Vargas; Natali Senocak; Julia G Shaw; Robert W Buckheit; Kelley Alison Smith; Kate Morrow Guthrie
Journal:  Contraception       Date:  2015-08-11       Impact factor: 3.375

3.  Innovative sensory methods to access acceptability of mixed polymer semisoft ovules for microbicide applications.

Authors:  Toral Zaveri; Cordelia A Running; Lahari Surapaneni; Gregory R Ziegler; John E Hayes
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 4.  Vaginal drug distribution modeling.

Authors:  David F Katz; Andrew Yuan; Yajing Gao
Journal:  Adv Drug Deliv Rev       Date:  2015-04-28       Impact factor: 15.470

5.  User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.

Authors:  Kathleen M Morrow; Kristen Underhill; Jacob J van den Berg; Sara Vargas; Rochelle K Rosen; David F Katz
Journal:  Arch Sex Behav       Date:  2014-01-23

6.  A Qualitative Systematic Review of Women's Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies.

Authors:  Sara E Vargas; Miriam M Midoun; Melissa Guillen; Melissa L Getz; Kristen Underhill; Caroline Kuo; Kate M Guthrie
Journal:  Perspect Sex Reprod Health       Date:  2019-05-20

7.  The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.

Authors:  Kate M Guthrie; Joseph L Fava; Sara E Vargas; Rochelle K Rosen; Julia G Shaw; Erna M Kojic; Anthony S Ham; Lisa C Rohan; David Katz; Anacecilia Panameño; Christopher Colleran; David F Friend; Karen W Buckheit; Robert W Buckheit
Journal:  AIDS Res Hum Retroviruses       Date:  2020-11-03       Impact factor: 2.205

8.  Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.

Authors:  K M Guthrie; L Rohan; R K Rosen; S E Vargas; J G Shaw; D Katz; E M Kojic; A S Ham; D Friend; K W Buckheit; R W Buckheit
Journal:  Pharm Dev Technol       Date:  2017-06-21       Impact factor: 3.133

9.  A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability.

Authors:  Ethel D Weld; Hiwot Hiruy; Kate Morrow Guthrie; Joseph L Fava; Sara E Vargas; Karen Buckheit; Robert Buckheit; Hans Spiegel; Jennifer Breakey; Edward J Fuchs; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-13       Impact factor: 2.205

10.  Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.

Authors:  Lara E Pereira; Tyana Singletary; Amy Martin; Chuong T Dinh; Frank Deyounks; Angela Holder; Janet McNicholl; Karen W Buckheit; Robert W Buckheit; Anthony Ham; David F Katz; James M Smith
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.